Pathos AI's Big $365m Series D, and Other Bio Financings

Pathos AI's big $365m Series D, and other bio financings

Our round-up of recent biotech financings includes rounds for Pathos AI, Stylus Medicine, Haya Therapeutics, Therini Bio and Tiltbio

Pathos AI raises $365m for oncology drug development

Pathos AI has raised $365m in a Series D funding round to widen its AI-enabled platform to advance the development of oncology drugs.

AI-powered drug development startup Pathos AI closes $365M investment - SiliconANGLE

Pathos AI Inc., a startup using artificial intelligence to develop new oncology drugs, today announced that it has raised $365 million in a late-stage funding. The company didn’t disclose the investors in the Series D round. According to FierceBiotech, the raise included the participation of both new and existing Pathos backers. The company, which is […] The post AI-powered drug development startup Pathos AI closes $365M investment appeared firs…

Pathos AI collects $365M to fuel 'bulletproof' oncology trials and in-license more cancer drugs

Pathos AI, seeking to upend cancer drug development with artificial intelligence and large multimodal models, has raised the third-largest private funding round in biotech so far this year. In the industry's 25th megaround of 2025 ...

Pathos AI, which uses AI to develop oncology drugs, raised a $365M Series D at a $1.6B valuation, bringing its total funding to $467M, per PitchBook

Katherine Davis / Axios: Pathos AI, which uses AI to develop oncology drugs, raised a $365M Series D at a $1.6B valuation, bringing its total funding to $467M, per PitchBook  —  Pathos AI, a New York drug development startup, raised $365 million in a Series D at a $1.6 billion valuation.